Loopbaan van Bertrand Cayrol
Eerdere bekende functies van Bertrand Cayrol
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Société Innovatech du Grand Montréal | Corporate Officer/Principal | 01-01-1992 | 31-12-1996 |
Cytheris SA
 Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Directeur/Bestuurslid | 15-12-2009 | - |
Transfer Technologies Commercialisation Capital
 Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Private Equity Investor | 01-01-1997 | - |
Opleiding van Bertrand Cayrol
| Ecole Nationale Superieure de Chimie de Toulouse | Undergraduate Degree |
| McGill University | Doctorate Degree |
Statistieken
Internationaal
| Canada | 4 |
| Frankrijk | 3 |
Operationeel
| Private Equity Investor | 1 |
| Corporate Officer/Principal | 1 |
| Director/Board Member | 1 |
Sectoraal
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
| Société Innovatech du Grand Montréal | |
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Health Technology |
- Beurs
- Insiders
- Bertrand Cayrol
- Ervaring
